GeoVax Labs | 8-K: FY2025 Q3 Revenue Meets Estimate at USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0, meeting the estimate of USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.31.

Net Loss

• Net loss for the three-month period ended September 30, 2025, was $6,318,914, or $0.31 per share, compared to $5,815,468, or $0.91 per share, for the same period in 2024. For the nine-month period ended September 30, 2025, the net loss was $17,046,348, or $0.97 per share, compared to $16,729,642, or $4.52 per share, in 2024.

Revenue

• The company reported $0 in government contract revenues for the three-month period and $2,489,145 for the nine-month period ending September 30, 2025, compared to $2,789,484 and $3,090,161 for the same periods in 2024. The decrease is attributed to the termination of the BARDA contract.

Research and Development Expenses

• R&D expenses were $5,043,504 for the three-month period and $15,127,090 for the nine-month period ended September 30, 2025, compared to $7,402,884 and $16,105,480 for the same periods in 2024. The decrease is primarily due to discontinued costs associated with the BARDA contract termination and lower costs for the GEO-CM04S1 clinical trials.

General and Administrative Expenses

• G&A expenses were $1,329,711 for the three-month period and $4,559,346 for the nine-month period ended September 30, 2025, compared to $1,241,176 and $3,784,559 for the same periods in 2024. The increase is mainly due to higher personnel costs and stock-based compensation expenses.

Cash Position

• Cash balances were $5,008,997 as of September 30, 2025, compared to $5,506,941 as of December 31, 2024.

Outlook / Guidance

• GeoVax anticipates progressing directly to a Phase 3 clinical evaluation for its Mpox and smallpox vaccine, omitting Phase 1 and Phase 2 trials, based on recent regulatory guidance. The company is also planning a Phase 2 trial for Gedeptin in combination with pembrolizumab and fludarabine for head and neck cancer, targeted for the second half of 2026.